Bradmer Pharmaceuticals Inc. (TSXV:BMR.H) said Friday that costs associated with a pending business combination were mainly responsible for a widening in its first-quarter loss.The company, which trades on the Toronto Stock Exchange but is based in California and reports in U.S. currency, said it lost US$166,000 or a penny per share in the three months ended March 31.That compared with a loss of US$112,000 or two cents per share the same 2010 quarter.The company, involved in anti-cancer therapies, did not report any revenues for the three months ended March 31.The increased loss in 2011 is attributable to legal and due diligence expenses related to the proposed combination with P1 Energy Corp., it said in a release.At the end of the quarter, Bradmer had working capital of US$1.4 million compared with $1.5 million at the end of December.
Subscribe to:
Post Comments (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac... -
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma... -
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th... -
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y... -
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after... -
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ... -
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
No comments:
Post a Comment